MSFT vs PFE: Which Is the Better Buy?
Side-by-side comparison of Microsoft Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Microsoft Corporation · Technology
$379.40
+45.0% upside to fair value
Grade A
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
MSFT has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MSFT |
PFE |
| Current Price |
$379.40 |
$25.22 |
| Fair Value Estimate |
$550.13 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$2,818.3B |
$143.7B |
| Forward P/E |
22.5x
|
19.2x
|
| EV / EBITDA |
14.2x
|
12.3x
|
| Price / Sales |
8.9x
|
2.3x
|
| Price / FCF |
38.6x
|
15.2x
|
| Revenue Growth YoY |
+18.3%
|
+5.4%
|
| Gross Margin |
68.3%
|
69.3%
|
| Operating Margin |
46.8%
|
23.4%
|
| Return on Equity |
33.1%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.59%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Microsoft Corporation is a leading global technology company specializing in cloud computing, productivity software, and enterprise platforms. The company benefits from a very strong and widening competitive moat supported by scale, switching costs, an integrated ecosystem, and disciplined capital allocation including large buybacks and dividends. Its business quality is high, demonstrated by a 3…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
MSFT |
PFE |
| Zone Low |
$412.60 |
$19.44 |
| Zone High |
$467.61 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|